This study reviews ancestral differences in the genetics of the LPA gene, risk categories of
elevated lipoprotein (a)[Lp (a)] as defined by guidelines, ancestry-specific Lp (a) risk …

Objectives: The purpose of this study was to assess the association of apolipoprotein
(a)(apo [a]) isoforms with cardiovascular disease risk. Background: Although circulating …

An elevated serum level of lipoprotein (a)(Lp [a]) may be an independent risk factor for
atherosclerotic disease, but the relation of Lp (a) to aortic valve (AV) sclerosis has not been …

Since its identification by Kåre Berg in 1963, lipoprotein (a)[Lp (a)] has become a focus of
research interest owing to the results of case-control and prospective studies linking …

Background Pelacarsen is a liver-targeted antisense oligonucleotide that potently lowers
lipoprotein (a)[Lp (a)] levels. Its safety and efficacy in diverse populations has not been …

Abstract Lipoprotein (a)(Lp (a)) was determined in 1527 individuals participating in the
Northern Sweden WHO MONICA project for monitoring of cardiovascular risk factors in the …

The present study was designed to confirm the transient increases of plasma Lp (a) levels as
an acute-phase reactant and to clarify the significance of these increases with the use of …

OBJECTIVES.: This study was undertaken to examine the influence of plasma lipoprotein
(a)[Lp (a)] levels on coronary endothelial vasomotor function. BACKGROUND …

Cardiovascular risk remains uncertain in patients with cardiovascular disease despite
achieving target lipid levels. Serum levels of lipoprotein (a)[Lp (a)] can be risk factors for …

Introduction There is abundant evidence that elevated lipoprotein (a)[LP (a)] associates with
cardiovascular risk. Most lipid modifying therapies don't reduce Lp (a), but new technologies …